Breaking News Instant updates and real-time market news.

AMGN

Amgen

$167.34

0.53 (0.32%)

08:54
10/04/16
10/04
08:54
10/04/16
08:54

Amgen, Nuevolution announce strategic collaboration in oncology, neuroscience

Nuevolution AB announced that Amgen and Nuevolution have entered into a multiple target research collaboration to develop and commercialize novel therapeutics in the areas of oncology and neuroscience. Nuevolution will apply its Chemetics drug discovery platform to discover and advance potential therapeutics of interest to Amgen. The research collaboration brings together Nuevolution's proprietary drug discovery platform with Amgen's disease expertise and drug development capabilities. Under the terms of the agreement, Amgen has an exclusive option to obtain all rights to successfully developed programs. Nuevolution is eligible to receive a license fee payment upon option exercise and milestone payments upon achievement of specified research, development and commercial milestones, amounting up to $410M per target. Nuevolution would also be entitled to receive royalties on future sales. Additional financial details are not being disclosed. Nuevolution will be responsible for the early research phase and Amgen will work collaboratively with Nuevolution during late-stage research. Amgen will be fully responsible for preclinical development, clinical development and commercialization worldwide.

  • 07

    Oct

  • 05

    Nov

  • 06

    Nov

  • 19

    Jul

AMGN Amgen
$167.34

0.53 (0.32%)

09/01/16
09/01/16
NO CHANGE

Amgen's sBLA for Blincyto approved by FDA
Amgen's supplemental Biologics License Application for Blincyto has been approved by the FDA to include new data supporting the treatment of pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This indication is approved under accelerated approval, and continued approval may be contingent upon verification of clinical benefit in subsequent trials. The approval is based on results from the Phase 1/2 '205, an open-label, multicenter, single-arm trial, which evaluated the efficacy and safety of BLINCYTO in pediatric patients with relapsed or refractory B-cell precursor ALL. Blincyto was granted breakthrough therapy, priority review and orphan drug designations by FDA, and is now approved in the U.S. for the treatment of Ph- relapsed or refractory B-cell precursor ALL. In November 2015, BLINCYTO was granted conditional marketing authorization in the European Union for the treatment of adults with Ph- relapsed or refractory B-cell precursor ALL.
09/27/16
GSCO
09/27/16
NO CHANGE
Target $206
GSCO
Conviction Buy
Goldman surprised by Amgen's Kyprolis outcome in first-line multiple myeloma
Last night, Amgen announced Phase 3 Kypolis CLARION study did not meet the primary endpoint in first-line multiple myeloma. Goldman analyst Terence Flynn was surprised by this outcome given the prior positive superiority data for Kyprolis versus Velcade in the Phase III ENDEAVOR trial. Flynn sees risk to his Kyprolis $1B sales estimate in a first-line setting, but awaits for additional details from the call and further information regarding another ongoing Phase III trial. He expects Amgen shares to be weak on the news but said the company has additional drivers beyond Kyprolis including Repatha for high cholesterol and Erenumab for migraine with additional data expected in 2H 2016 and Q1 2017. Flynn remains Conviction Buy rated on Amgen and maintains his $206 price target.
09/27/16
PIPR
09/27/16
NO CHANGE
PIPR
Overweight
Amgen's Kyprolis in good shape despite trial miss, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says Amgen's Kyprolis is still likely to be viewed as a "potent backbone, with the right drugs" after a Phase 3 study in front-line myeloma failed to reach its primary endpoint. The analyst believes the impact of the failed trial on Kyprolis use will be limited and he reiterates an Overweight rating on Amgen.
09/29/16
PIPR
09/29/16
NO CHANGE
Target $10
PIPR
Overweight
Arrowhead price target raised to $10 from $8 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals (ARWR) to $10 after the company licensed two preclinical cardiovascular RNAi drugs with Amgen (AMGN). Amgen is the "ideal partner" and Arrowhead's balance sheet is now "meaningfully" strengthened, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Arrowhead.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

15:17
06/28/17
06/28
15:17
06/28/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
06/28/17
06/28
15:16
06/28/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLCO

Melco Resorts & Entertainment

$22.71

-0.29 (-1.26%)

15:10
06/28/17
06/28
15:10
06/28/17
15:10
Options
Melco Resorts with a bullish short-term option play »

Melco Resorts with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:05
06/28/17
06/28
15:05
06/28/17
15:05
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

SIEGY

Siemens

$70.08

-0.19 (-0.27%)

, BDRBF

Bombardier

$1.83

-0.0236 (-1.27%)

15:02
06/28/17
06/28
15:02
06/28/17
15:02
Periodicals
Breaking Periodicals news story on Siemens, Bombardier »

Siemens, Bombardier…

SIEGY

Siemens

$70.08

-0.19 (-0.27%)

BDRBF

Bombardier

$1.83

-0.0236 (-1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

T

AT&T

$37.89

0.186 (0.49%)

15:00
06/28/17
06/28
15:00
06/28/17
15:00
Options
AT&T attracts downside put buyers »

AT&T attracts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POT

Potash

$16.34

-0.015 (-0.09%)

14:55
06/28/17
06/28
14:55
06/28/17
14:55
Options
Potash put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CARA

Cara Therapeutics

$26.42

1.01 (3.97%)

, NKTR

Nektar

$18.82

-0.915 (-4.64%)

14:46
06/28/17
06/28
14:46
06/28/17
14:46
Hot Stocks
Before the Move: Watch Cara Therapeutics into osteoarthritis pain results »

Cara Therapeutics (CARA)…

CARA

Cara Therapeutics

$26.42

1.01 (3.97%)

NKTR

Nektar

$18.82

-0.915 (-4.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 06

    Jul

NRG

NRG Energy

$17.41

0.2001 (1.16%)

14:45
06/28/17
06/28
14:45
06/28/17
14:45
Options
NRG Energy call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDEN

Golden Entertainment

$20.36

-0.37 (-1.78%)

14:43
06/28/17
06/28
14:43
06/28/17
14:43
Hot Stocks
Golden Entertainment announces approval for Illinois gaming terminal license »

Golden Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LB

Labarge

$54.33

-0.085 (-0.16%)

14:30
06/28/17
06/28
14:30
06/28/17
14:30
Options
6X average daily volume in L Brands driven by a three-way spread »

6X average daily volume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FENX

Fenix Parts

$1.57

0.08 (5.37%)

14:29
06/28/17
06/28
14:29
06/28/17
14:29
Hot Stocks
Fenix Parts plunges after Nasdaq delisting notice »

Shares of microcap Fenix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HL

Hecla Mining

$5.25

0.075 (1.45%)

14:28
06/28/17
06/28
14:28
06/28/17
14:28
Hot Stocks
Breaking Hot Stocks news story on Hecla Mining »

Hecla Mining trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMPH

KemPharm

$3.45

0.05 (1.47%)

14:25
06/28/17
06/28
14:25
06/28/17
14:25
Conference/Events
KemPharm to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

HL

Hecla Mining

$5.25

0.075 (1.45%)

14:24
06/28/17
06/28
14:24
06/28/17
14:24
Earnings
Hecla Mining sees Q2 revenue of $127M-$137M, consensus $145.85M »

Hecla Mining announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HL

Hecla Mining

$5.25

0.075 (1.45%)

14:21
06/28/17
06/28
14:21
06/28/17
14:21
Hot Stocks
Hecla Mining to offer $500M of senior notes »

Hecla Mining announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVA

Sinovac Biotech

$6.34

-0.07 (-1.09%)

14:20
06/28/17
06/28
14:20
06/28/17
14:20
Hot Stocks
Sinobioway Consortium confirms Sinovac Biotech offer raised to $8 per share »

Shandong Sinobioway…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
06/28/17
06/28
14:17
06/28/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
06/28/17
06/28
14:16
06/28/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QQQ

PowerShares QQQ Trust

$138.03

-2.55 (-1.81%)

14:10
06/28/17
06/28
14:10
06/28/17
14:10
Options
Defensive option play in the PowerShares QQQ »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGX

Argan

$62.40

0.9 (1.46%)

14:08
06/28/17
06/28
14:08
06/28/17
14:08
Initiation
Argan initiated  »

Argan initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HL

Hecla Mining

$5.24

0.07 (1.35%)

14:05
06/28/17
06/28
14:05
06/28/17
14:05
Hot Stocks
Breaking Hot Stocks news story on Hecla Mining »

Hecla Mining trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:05
06/28/17
06/28
14:05
06/28/17
14:05
General news
U.S. equities are extending their bull run »

U.S. equities are…

14:00
06/28/17
06/28
14:00
06/28/17
14:00
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

13:58
06/28/17
06/28
13:58
06/28/17
13:58
General news
Averages, internals remain strong in afternoon trading »

Stocks remain sharply…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.